bioAffinity Share Price
NASDAQ: BIAF | Micro Cap | HealthcarebioAffinity Stock Performance
bioAffinity Share Price Chart
bioAffinity Quarterly Profit & Loss
All figures in USD
bioAffinity Annual Profit & Loss
All figures in USD
bioAffinity Balance Sheet
All figures in USD Million
bioAffinity Cash Flow
All figures in USD Million
About bioAffinity
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
bioAffinity Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $2.98 | $1.73 | -42.14% |
Oct 2026 | $6.66 | $2.99 | -55.87% |
Sep 2026 | $7.51 | $6.78 | +32.32% |
Aug 2026 | $0.59 | $5.12 | +716.59% |
Jul 2026 | $0.85 | $0.63 | -23.35% |
Jun 2026 | $1.74 | $0.82 | -51.02% |
May 2026 | $2.41 | $1.67 | -33.20% |
Apr 2026 | $4.32 | $2.50 | -35.23% |
Mar 2026 | $1.01 | $3.86 | +274.76% |
Feb 2026 | $1.18 | $1.03 | -10.43% |
Jan 2026 | $1.25 | $1.15 | -7.26% |
Dec 2025 | $1.54 | $1.24 | -15.93% |